Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
Abstract Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICI...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e1027f0afb7f466d803752a48a7d5614 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|